Logo
Logo

About Iron Sucrose (Available For Selected Markets) API

Product
  • Therapeutic CategoryNephrology

  • CAS Number

    8047-67-4

  • API Technology

    Iron Product

  • Dose Form

    Injectable

  • Dr Reddy's Development Status

    Available

  • Available Regulatory Filing

    USDMF, Brazil DMF

Mechanism of Action

Venofer is an aqueous complex of poly-nuclear iron (III)-hydroxide in sucrose. Following intravenous administration, Venofer is dissociated into iron and sucrose and the iron is transported as a complex with transferrin to target cells including erythroid precursor cells. The iron in the precursor cells is incorporated into hemoglobin as the cells mature into red blood cells.

Indication

Venofer is an iron replacement product indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease (CKD).

Related APIs

Ferric Carboxymaltose

Nephrology

arrow

Iron Sucrose (Available For Selected Markets)

Nephrology

arrow

Roxadustat Monohydrate - Form A

Nephrology

arrow

Voclosporin

Nephrology

arrow

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone

Related Resources

Colloidal Iron Complex Formulations – Understanding and Developing the Process

Colloidal Iron Complex Formulations – Understanding and Developing the Process

This whitepaper describes the challenges involved in developing iron-carbohydrate complexes, including the parameters required to demonstrate physicochemical equivalence and summarises our expertise in addressing them. Iron carbohydrate complexes are a hybrid of inorganic and organic molecules. The molecule's key structural elements are architected /governed by the defined process unit operations and materials used in the process. Any subtle variation in the process unit operation can alter the structural features of the iron carbohydrate complexTo continue reading, please fill in the contact form below
Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.